Fortrea (FTRE) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Q3 2024 revenue was $674.9 million, down 5.4% year-over-year, with a book-to-bill ratio of 1.23x and backlog rising to $7.6 billion, up 6.2% year-over-year.
Adjusted EBITDA was $64.2 million, down 5.9% year-over-year but up 16.3% sequentially; margin expansion and cost optimization initiatives are ongoing.
Net loss for Q3 2024 was $18.5 million, with adjusted net income per diluted share at $0.23.
Over 90% of IT systems migrated post-spin, with progress on exiting transition services agreements and operational separation from the former parent.
Customer and net promoter scores improved post-spin, with external recognition for operational excellence and DEI initiatives.
Financial highlights
Q3 2024 revenue was $674.9 million, down 5.4% year-over-year; adjusted EBITDA was $64.2 million, margin at 9.5%.
Adjusted net income was $20.7 million, up 3% year-over-year; adjusted diluted EPS was $0.23.
Free cash flow for the first nine months was $217 million; operating cash flow was $245.7 million.
Net interest expense decreased to $22.4 million, benefiting from debt repayments; gross debt was $1,142.0 million.
Basic and diluted loss per share from continuing operations was $(0.21) for Q3 2024.
Outlook and guidance
Full-year 2024 revenue guidance is $2,700–$2,725 million; adjusted EBITDA guidance is $220–$240 million.
Q4 2024 adjusted EBITDA expected to improve to $74–94 million, driven by service fee revenue growth and cost savings.
Majority of TSAs expected to be exited by year-end, supporting SG&A cost reduction in 2025.
2025 guidance to be provided in Q1 2025, pending TSA exit timing and Q4 business awards.
Management expects compliance with all debt covenants for at least the next 12 months.
Latest events from Fortrea
- 2025 results met guidance; 2026 targets margin growth and stability despite goodwill impairment.FTRE
Q4 202526 Feb 2026 - Debt reduction, execution focus, and margin improvements drive confidence in 2024 guidance.FTRE
Fireside Chat3 Feb 2026 - Strong book-to-bill, commercial transformation, and debt reduction drive improved outlook.FTRE
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q2 2024 saw revenue and earnings decline, but sequential EBITDA and cash flow improved as debt fell.FTRE
Q2 20241 Feb 2026 - Accelerating clinical trials with digital innovation and operational excellence in a $40B market.FTRE
44th Annual J.P. Morgan Healthcare Conference30 Jan 2026 - Balanced growth, disciplined execution, and tech-driven innovation drive margin expansion.FTRE
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 2025 results show strong cash flow, cost savings, and raised FY2025 guidance in a $40B market.FTRE
Investor presentation13 Jan 2026 - Strategic changes, tech innovation, and cost discipline drive growth and margin expansion.FTRE
Evercore ISI 8th Annual HealthCONx Conference12 Dec 2025 - Bookings rebound, cost savings drive margin focus, and debt reduction remains a top priority.FTRE
Citi Annual Global Healthcare Conference 20253 Dec 2025